# Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D

> **NCT04074421** · PHASE4 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 240 (estimated)

## Conditions studied

- IBS - Irritable Bowel Syndrome
- Gut Microbiota

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Probiotic Formula
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04074421
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-10
- **Primary completion:** 2022-06
- **Final completion:** 2022-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2020-07-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074421, "Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT04074421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*